Cerence Inc. (CRNC)

Akoya Biosciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Revenue	254.25	331.5	294.48	327.89	387.18	330.97
Revenue Growth (YoY)	-27.06%	12.57%	-10.19%	-15.31%	16.98%	9.12%
Cost of Revenue	75.67	87.13	94.75	94.18	93.56	99.51
Gross Profit	178.58	244.38	199.73	233.71	293.62	231.45
Selling, General & Admin	66.7	74.19	85.41	73.75	95.66	82.78
Research & Development	100.61	121.56	123.33	107.12	112.07	88.9
Operating Expenses	169.51	198.06	215.01	195.37	227.94	192.56
Operating Income	9.08	46.31	-15.28	38.34	65.69	38.89
Interest Expense	-12.32	-12.55	-14.77	-14.39	-14	-22.74
Interest & Investment Income	5.09	5.35	4.47	1.01	0.11	0.59
Currency Exchange Gain (Loss)	-0.49	-	-	-	-2.51	-2.4
Other Non Operating Income (Expenses)	2.69	2.53	1.11	-1.02	4.08	-1.64
EBT Excluding Unusual Items	4.05	41.64	-24.47	23.93	53.36	12.7
Merger & Restructuring Charges	-20.64	-13.48	-8.24	-2.35	-3.08	-4.73
Impairment of Goodwill	-357.08	-609.17	-	-213.72	-	-
Other Unusual Items	-5.37	-3.59	-3.68	-6.62	-2.01	-31.01
Pretax Income	-379.04	-584.61	-36.39	-198.75	48.27	-23.04
Income Tax Expense	-42.45	3.47	19.87	112.08	2.38	-4.72
Net Income	-336.59	-588.08	-56.25	-310.83	45.89	-18.32
Net Income to Common	-336.59	-588.08	-56.25	-310.83	45.89	-18.32
Shares Outstanding (Basic)	42	42	40	39	38	36
Shares Outstanding (Diluted)	42	42	40	39	39	36
Shares Change (YoY)	3.79%	3.55%	2.62%	-0.26%	7.85%	0.10%
EPS (Basic)	-7.93	-14.12	-1.40	-7.93	1.22	-0.50
EPS (Diluted)	-7.93	-14.12	-1.40	-7.93	1.17	-0.50
Free Cash Flow	37.76	12.2	2.37	-19.58	62.34	25.78
Free Cash Flow Per Share	0.89	0.29	0.06	-0.50	1.59	0.71
Gross Margin	70.24%	73.72%	67.82%	71.28%	75.84%	69.93%
Operating Margin	3.57%	13.97%	-5.19%	11.69%	16.96%	11.75%
Profit Margin	-132.39%	-177.40%	-19.10%	-94.80%	11.85%	-5.53%
Free Cash Flow Margin	14.85%	3.68%	0.81%	-5.97%	16.10%	7.79%
EBITDA	17.42	54.24	-3.24	58.58	91.95	65.83
EBITDA Margin	6.85%	16.36%	-1.10%	17.87%	23.75%	19.89%
D&A For EBITDA	8.34	7.93	12.04	20.24	26.26	26.94
EBIT	9.08	46.31	-15.28	38.34	65.69	38.89
EBIT Margin	3.57%	13.97%	-5.19%	11.69%	16.96%	11.75%
Effective Tax Rate	-	-	-	-	4.92%	-
Revenue as Reported	254.25	331.5	294.48	327.89	387.18	330.97

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q